Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a shot of your own blood ease menopause symptoms?

NCT ID NCT06028009

Symptom relief Sponsor: Medstar Health Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether injecting platelet-rich plasma (PRP) — made from a woman's own blood — into the vaginal wall can improve sexual function and reduce dryness caused by menopause. Thirty postmenopausal women with genitourinary syndrome of menopause will receive either PRP or a saline injection, and their symptoms will be tracked using questionnaires. The goal is to see if this simple procedure offers relief without hormones.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
platelet-rich plasma (PRP)
What this could lead to
If it works, this could offer a new, natural option to ease vaginal dryness and improve sexual function for women going through menopause.
What could go wrong
This is a small, early-stage trial with only 30 participants, so results may not apply to everyone. PRP injections are not yet proven for this use, and there is a risk of discomfort or infection from the procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women (assigned female at birth) at least 18 years old with a clinical diagnosis of GSM * Sexually active with at least one episode of sexual activity per week in the preceding 4 weeks defined as follows: Partnered or solo penetrative or non-penetrative stimulation of the clitoris or vagina * English-speaking * Willingness and able to comply with the study requirements Exclusion Criteria: * Symptomatic pelvic organ prolapse protruding beyond the hymen) * History of prior vaginal mesh or midurethral mesh sling surgery * History of pelvic radiation or genital tract malignancy * Current symptomatic pelvic organ prolapse (stage II or greater) * Active vulvar dermatoses or genitourinary infection * Unable to hold anticoagulation * Hormonal replacement therapy (systemic, local, or vaginal) within 3 months of participation * Pregnancy or pre-menopausal status

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Genitourinary syndrome of menopause are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

familial pityriasis rubra pilaris physiological sexual disorder postmenopausal atrophic vaginitis Sexual Dysfunctions, Psychological

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Genitourinary syndrome of menopause Postmenopausal symptoms PRP Sexual function disturbances Vaginal atrophy

Contacts and locations

Locations

  • MedStar Lafayette Medical Centre

    Washington D.C., District of Columbia, 20036, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.